PURPOSE: To compare the efficiency and safety of accelerated corneal cross-linking in pediatric patients with progressive keratoconus. METHODS: In this retrospective interventional case series, 44 eyes of 38 pediatric patients with progressive keratoconus were enrolled. All consecutive patients underwent accelerated corneal cross-linking with settings of 30 mW/cm(2) for 4 minutes, corresponding to a total dose of 7.2 J. The efficacy and safety of the procedure were assessed over a 24-month follow-up period. RESULTS: Mean ± standard deviation age of 10 girls and 28 boys was 15.3 ± 2.1 years (range: 9 to 18 years). Uncorrected distance visual acuity improved significantly from 0.52 ± 0.36 to 0.39 ± 0.26 logMAR (P = .002), and corrected distance visual acuity improved significantly from 0.38 ± 0.24 to 0.30 ± 0.20 logMAR (P < .001). Mean spherical and cylindrical refraction were not significantly altered (P > .001 for both). At the last follow-up visit, the flat keratometry value decreased from baseline from 46.4 ± 3.0 to 46.0 ± 2.9 diopters and the steep keratometry value decreased from 50.6 ± 4.2 to 50.1 ± 4.0 diopters (P < .001 for both). The total higher-order aberrations, coma, and astigmatism II values were also significantly decreased at 24 months after treatment (P < .05 for all). No serious complications were recorded during the follow-up. CONCLUSIONS: The findings revealed that accelerated corneal cross-linking halted the keratoconus progression without relevant side effects in pediatric patients over a 24-month follow-up period. Visual acuity, keratometric values, and corneal aberrations also improved. Copyright 2014, SLACK Incorporated.
PURPOSE: To compare the efficiency and safety of accelerated corneal cross-linking in pediatric patients with progressive keratoconus. METHODS: In this retrospective interventional case series, 44 eyes of 38 pediatric patients with progressive keratoconus were enrolled. All consecutive patients underwent accelerated corneal cross-linking with settings of 30 mW/cm(2) for 4 minutes, corresponding to a total dose of 7.2 J. The efficacy and safety of the procedure were assessed over a 24-month follow-up period. RESULTS: Mean ± standard deviation age of 10 girls and 28 boys was 15.3 ± 2.1 years (range: 9 to 18 years). Uncorrected distance visual acuity improved significantly from 0.52 ± 0.36 to 0.39 ± 0.26 logMAR (P = .002), and corrected distance visual acuity improved significantly from 0.38 ± 0.24 to 0.30 ± 0.20 logMAR (P < .001). Mean spherical and cylindrical refraction were not significantly altered (P > .001 for both). At the last follow-up visit, the flat keratometry value decreased from baseline from 46.4 ± 3.0 to 46.0 ± 2.9 diopters and the steep keratometry value decreased from 50.6 ± 4.2 to 50.1 ± 4.0 diopters (P < .001 for both). The total higher-order aberrations, coma, and astigmatism II values were also significantly decreased at 24 months after treatment (P < .05 for all). No serious complications were recorded during the follow-up. CONCLUSIONS: The findings revealed that accelerated corneal cross-linking halted the keratoconus progression without relevant side effects in pediatric patients over a 24-month follow-up period. Visual acuity, keratometric values, and corneal aberrations also improved. Copyright 2014, SLACK Incorporated.
Authors: Hala El Rami; Elias Chelala; Ali Dirani; Ali Fadlallah; Henry Fakhoury; Carole Cherfan; George Cherfan; Elias Jarade Journal: Biomed Res Int Date: 2015-09-29 Impact factor: 3.411